Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER
Bliv medlem
Log ind

Nyheder om BSLN.S

RB Finansnyheder
OMX Børsmeddelelser
Insiderhandel
Årsrapporter
Finanskalender

19/2 2019 07:15 Basilea reports strong revenue growth and significant pipeline progress for full-year 2018

8/2 2019 07:15 Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment to Basilea from Pfizer

7/2 2019 07:15 Basilea announces change in the Management Committee - Adesh Kaul appointed CFO

24/1 2019 07:15 Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in urothelial cancer

9/1 2019 07:15 Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA)

7/1 2019 07:15 Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018

4/1 2019 07:15 Basilea presenting at the 37th Annual J. P. Morgan Healthcare Conference - delivering on its strategy

10/12 2018 07:15 Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea

14/8 2018 07:15 Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline

13/8 2018 07:15 Basilea reports on first Cresemba® approval in MENA region

9/8 2018 07:15 Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)

19/7 2018 07:15 Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America

26/6 2018 07:15 Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma

5/6 2018 07:15 Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting

15/5 2018 07:15 Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC

27/4 2018 07:15 Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management

20/4 2018 07:15 Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

18/4 2018 18:06 Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders

18/4 2018 07:15 Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole

17/4 2018 07:15 Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

9/4 2018 07:15 Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma

6/3 2018 07:15 Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana

1/3 2018 07:15 Basilea names Adesh Kaul as new member of its Management Committee

27/2 2018 07:15 Basilea reports significantly improved financial results in 2017

23/2 2018 07:15 Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract